Duration of Contact Precautions for Acute-Care Settings
February 2018 – Update Published
To review the new update, please click on the link below to be redirected:
CutisPharma announced ON January 29, 2018 that the US Food and Drug Administration (FDA) has approved FIRVANQ™ (vancomycin hydrochloride) for oral solution, for the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains. “We are pleased to announce the FDA approval of FIRVANQ,” said Neal I. Muni, MD, MSPH, Chief Executive Officer of CutisPharma. “FIRVANQ’s approval is an important step forward to providing patients the only FDA-approved vancomycin oral liquid treatment option for Clostridium difficile associated diarrhea, a life-threatening condition that affects over a half-million patients in the United States annually.”
Upon its launch, which is targeted to be April 2, 2018, FIRVANQ™ will replace CutisPharma’s FIRST®-Vancomycin Unit-of-Use Compounding Kit, which has been available to pharmacists that need a convenient, accurate, and compliant way to compound vancomycin oral liquid therapy. FIRVANQ™ will be commercially available in 25 mg/mL and 50 mg/mL strengths in convenient 150 mL and 300 mL sizes. FIRVANQ™ is designed to be easy to use and has the potential to be a cost-effective alternative to existing vancomycin therapies. For more information visit CutisPharma Website: www.cutispharma.com
ZINPLAVA (bezlotoxumab) is now available for prescription.
Ordering information is available on the brand website:
What is Zinplava™ ?
ZINPLAVA™ is indicated to reduce recurrence of Clostridium difficile infection (CDI) in patients 18 years of age or older who are receiving antibacterial drug treatment of CDI and are at a high risk for CDI recurrence.
ZINPLAVA is not indicated for the treatment of CDI.
ZINPLAVA is not an antibacterial drug.
ZINPLAVA should only be used in conjunction with antibacterial drug treatment of CDI.
Full prescribing information can be read at
http://www.merck.com/product/usa/pi_circulars/z/zinplava/zinplava_pi.pdf
The Merck Access Program can help answer physician’s questions about:
Insurance coverage for patients
Prior Authorizations and Appeals
Coding and Billing
Potential financial assistance options for eligible patients
Full program details can be found at:
https://www.merckaccessprogram-zinplava.com/hcp/
Also, Information about co-pay assistance for eligible, privately insured patients
Information about available independent assistance foundation support.
*PLEASE NOTE – The C Diff Foundation does not endorse any product, medication, and/or clinical study in progress and available. All website postings are strictly for informational purposes only.
…………………………………………………………………………………………………
SEPSIS AWARENESS INFORMATION:
………………………………………………………………………………
ANTIBIOTIC INFORMATION:
Antibiotic-Resistance CDC Links Of Interest:
Core Elements:
https://www.cdc.gov/getsmart/healthcare/implementation/core-elements.html
https://www.cdc.gov/longtermcare/prevention/antibiotic-stewardship.html
Links to Patient Safety Atlas
Antibiotic Resistance Patient Safety Atlas: Hospital Antibiotic Stewardship Programs by State Data (2014-2015) https://gis.cdc.gov/grasp/PSA/indexST.html
CDC Standard Precautions and OSHA Mandated PPE
…………………………………………………………………………………
Utilize the healthcare professional prevention guideline and stay safe.
For Clinicians: 6 Steps to C. diff. Prevention
- Prescribe and use antibiotics carefully. About 50% of all antibiotics given are not needed, unnecessarily raising the risk of C. difficile infections.
- Test for C. difficile when patients have diarrhea while on antibiotics or within several months of taking them.
- Isolate patients with C. difficile immediately.
- Wear gloves and gowns when treating patients with C. difficile, even during short visits. Hand sanitizer does not kill C. difficile, and hand washing may not be sufficient.
- Clean room surfaces with bleach or another EPA-approved, spore-killing disinfectant after a patient with C. difficile has been treated there.
- When a patient transfers, notify the new facility if the patient has a C. difficile infection.
(1) CDC
Released by the CDC : February 2015
………………………………………………………………………………………………..
Merck — known as MSD outside the United States and Canada, on October 22, 2016 announced that the U.S. Food and Drug Administration (FDA) has approved
ZINPLAVA™ (bezlotoxumab) Injection 25 mg/mL.
Merck anticipates making ZINPLAVA available in first quarter 2017.
ZINPLAVA is indicated to reduce recurrence of Clostridium difficile infection (CDI) in patients 18 years of age or older who are receiving antibacterial drug treatment of CDI and are at high risk for CDI recurrence.
ZINPLAVA is not indicated for the treatment of CDI.
ZINPLAVA is not an antibacterial drug. ZINPLAVA should only be used in conjunction with antibacterial drug treatment of CDI.
Please see Prescribing Information for ZINPLAVA (bezlotoxumab) at http://www.merck.com/product/usa/pi_circulars/z/zinplava/zinplava_pi.pdf
Patient Information for ZINPLAVA at http://www.merck.com/product/usa/pi_circulars/z/zinplava/zinplava_ppi.pdf
CDI is caused by bacteria that produce toxins, including toxin B. Symptoms of CDI include mild-to-severe diarrhea, abdominal pain and fever. The incidence of recurrent CDI is higher in certain patient populations, including people 65 years of age or older and those with compromised immune systems.
“For generations, Merck has been steadfast in its commitment to fighting infectious diseases – and that commitment continues today. ZINPLAVA is a human monoclonal antibody that binds to C. difficile toxin B and neutralizes its effects,” said Dr. Nicholas Kartsonis, vice president of clinical development, infectious diseases, Merck Research Laboratories.
Selected safety information about ZINPLAVA
Heart failure was reported more commonly in the two Phase 3 clinical trials in ZINPLAVA-treated patients compared to placebo-treated patients. These adverse reactions occurred primarily in patients with underlying congestive heart failure (CHF). In patients with a history of CHF, 12.7% (15/118) of ZINPLAVA-treated patients and 4.8% (5/104) of placebo-treated patients had the serious adverse reaction of heart failure during the 12-week study period. Additionally, in patients with a history of CHF, there were more deaths in ZINPLAVA-treated patients [19.5% (23/118)] than in placebo-treated patients [12.5% (13/104)] during the 12-week study period. The causes of death varied, and included cardiac failure, infections, and respiratory failure. In patients with a history of CHF, ZINPLAVA (bezlotoxumab) should be reserved for use when the benefit outweighs the risk.
The most common adverse reactions occurring within 4 weeks of infusion with a frequency greater than placebo and reported in ≥4% of patients treated with ZINPLAVA and Standard of Care (SoC) antibacterial drug therapy vs placebo and SoC antibacterial drug therapy included nausea (7% vs 5%), pyrexia (5% vs 3%) and headache (4% vs 3%).
Serious adverse reactions occurring within 12 weeks following infusion were reported in 29% of ZINPLAVA-treated patients and 33% of placebo-treated patients. Heart failure was reported as a serious adverse reaction in 2.3% of ZINPLAVA-treated patients and 1.0% of placebo-treated patients.
In ZINPLAVA-treated patients, 10% experienced one or more infusion specific adverse reactions compared to 8% of placebo-treated patients, on the day of or the day after, the infusion. Infusion specific adverse reactions reported in ≥0.5% of patients receiving ZINPLAVA and at a frequency greater than placebo were nausea (3%), fatigue (1%), pyrexia (1%), dizziness (1%), headache (2%), dyspnea (1%) and hypertension (1%). Of these patients, 78% experienced mild adverse reactions, and 20% of patients experienced moderate adverse reactions. These reactions resolved within 24 hours following onset.
As with all therapeutic proteins, there is a potential for immunogenicity following administration of ZINPLAVA. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to bezlotoxumab in two Phase 3 studies with the incidence of antibodies in other studies or to other products may be misleading. Following treatment with ZINPLAVA in these two studies, none of the 710 evaluable patients tested positive for treatment-emergent anti-bezlotoxumab antibodies.
About bezlotoxumab
Bezlotoxumab was developed by researchers at the University of Massachusetts Medical School’s MassBiologics Laboratory in conjunction with Medarex (now part of Bristol-Myers Squibb), and was licensed to Merck in 2009.
Please see Prescribing Information for ZINPLAVA (bezlotoxumab) at http://www.merck.com/product/usa/pi_circulars/z/zinplava/zinplava_pi.pdf
…………………………………………………….
FDA Approved Treatment of CDAD
Dificid (fidaxomicin)
DIFICID is a macrolide antibacterial drug indicated in adults (≥18 years of age) for treatment of Clostridium difficile-associated diarrhea (CDAD).
To reduce the development of drug-resistant bacteria and maintain the effectiveness of DIFICID and other antibacterial drugs, DIFICID should be used only to treat infections that are proven or strongly suspected to be caused by C difficile.
Healthcare Professionals please click on the following links to review additional information
https://www.merckconnect.com/dificid/overview.html#
FOR PATIENTS AND PHYSICIANS: PATIENT ASSISTANCE PROGRAM INFORMATION *
To learn more about the parameters and eligibility requirements for the Patient Assistance Program for DIFICID, and all Merck medicines, call 1-800-727-5400
or (908) 423-1000,
Press option 1 for the Patient Assistance Program. A Merck Representative will assist the patient and physicians with program guidelines and document forms.
-
For general questions about MERCK products
1-800-442-5624
Monday – Thursday 8 AM – 8 PM ET
Friday 8 AM – 6 PM ET
Hours are subject to change. -
For adverse event reporting
1-866-342-5683
If you wish to report an adverse event for a specific Merck product, please call the Merck National Service Center at any time. -
For general questions about Merck Connect
1-800-489-5119
Monday – Friday 8 AM – 7 PM ET
Voice messages left after business hours will be returned by the end of the next business day.
Network Pharmacies Can Help Support Patients Prescribed DIFICID
Patient support features include: Information and assistance regarding access to therapy (including benefits investigation and reimbursement requirements), Product availability, Next-day delivery of medications, Disease-related educational materials for patients, and 24-hour patient counseling services
For more information, please visit: https://www.merckconnect.com/dificid/pharmacy-network.html
♥ Savings Coupon and Information For Patients – click on the link below to access coupon:
*Please note – The C Diff Foundation does not endorse this product or any product and this posting is strictly for informational purposes only.
————————————————————–
Contact us at 1-844-FOR-CDIF to receive your complimentary DVD “Raising C. diff. Awareness for Healthcare Providers” and share this important information with your office staff and colleagues.
